


PYFA

Annual General Meeting of Shareholders 2026

PT PYRIDAM FARMA TBK

Thursday, June 11th 2026

Finance Hall, Jakarta



Disclaimer:

In the event of any changes or additions to these Annual GMS Agenda Materials, the Company shall promptly disclose such information to the Shareholders through the Company's official website.

First Agenda

Approval of the Annual Report, Sustainability Report, and Ratification of the Company's Financial Statements for the financial year ended on December 31, 2025, as well as granting full release and discharge (volledig acquit et de charge) to the members of the Board of Directors and the Board of Commissioners for the management and supervision actions carried out during the financial year ended on December 31, 2025.

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter a of the Company's Articles of Association
- (ii) Article 13 paragraph (6) of the Company's Articles of Association
- (iii) Article 66, Article 67, Article 68, and Article 69 of Law Number 40 of 2007 concerning Limited Liability Companies, as amended by Law Number 6 of 2023 concerning the Enactment of Government Regulation in Lieu of Law Number 2 of 2022 concerning Job Creation into Law (“**Company Law**”)

Elucidation:

- In the Annual General Meeting of Shareholders (“the Meeting”), the Company will present and seek approval and/or ratification from the Shareholders for the Annual Report and Sustainability Report for the financial year which ended on December 31, 2025. This shall encompass, inter alia, the oversight report of the Board of Commissioners and the Company's audited financial statements for the financial year which ended on December 31, 2025. The consolidated financial statements have been audited by the Public Accounting Firm Purwanto, Susanti & Surja, a member firm of EY, and reflect fairly, in all material respects, the consolidated financial position of PT Pyridam Farma Tbk and its subsidiaries as of December 31, 2025, alongside its consolidated financial performance and cash flows for the year then ended, in compliance with the Indonesian Financial Accounting Standards, as set forth in the Independent Auditor's Report No. 00432/2.1505/AU.1/05/1810-2/1/III/2026, dated December 31, 2025.
- The aforementioned Annual Report, Sustainability Report, and Financial Statements can be accessed and downloaded via the PT Pyridam Farma Tbk official website (www.pyfa.co.id).

Second Agenda

Determination on the utilization of the Company's Net Profit/Net Loss for the financial year ended on December 31, 2025.

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter b of the Company's Articles of Association
- (ii) Article 70 and Article 71 of the Company Law

Elucidation:

- The Company's Net Loss for the financial year which ended on December 31, 2025, amounted to Rp379,670,109,302.- Further details regarding the Company's Net Loss for the 2025 financial year can be referred to in the 2025 Financial Statements, which is available on the Company's website.

Third Agenda

Determination of Remuneration for Members of the Board of Directors and the Board of Commissioners of the Company for the 2026 Financial Year.

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter e of the Company's Articles of Association
- (ii) Article 96 paragraph (1) and paragraph (2) and Article 113 of the Company Law

Elucidation:

- In consideration of the performance of the Board of Directors and the Board of Commissioners, and to ensure competitiveness and alignment with market dynamics, adjustments need to be made to the remuneration of the Company's Board of Directors and Board of Commissioners.

Fourth Agenda

Determination of a Public Accounting Firm to audit the Company's Consolidated Financial Statements for the financial year ending on December 31, 2026.

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter c juncto Article 13 paragraph (8) letter c of the Company's Articles of Association
- (ii) Article 59 paragraph (1) and (2) of OJK Regulation Number 15/POJK.04/2020 concerning the Plan and Implementation of the General Meeting of Shareholders of Public Companies (“**GMS POJK**”)

Elucidation:

- In consideration of the Company's current circumstances, the Company requires additional time to monitor and evaluate performance, **and to deliberate on the prospective public accountants** to be appointed based on recommendations from the Board of Commissioners and the Audit Committee, as well as other relevant objectives deemed necessary for the decision-making process.

Fifth Agenda

Reporting on the Realization of the Use of Proceeds from the Public Offering of Pyridam Farma Continuous Bonds I Phase III Year 2024, Pyridam Farma Continuous Bonds II Phase I Year 2025, and the Limited Public Offering to Shareholders for Capital Increase with Pre-emptive Rights I and Issuance of Series 1 Warrants.

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter f of the Company's Articles of Association
- (ii) Article 13 paragraph (1), (2), and (3) of POJK Number 40 of 2025 concerning the Use of Proceeds from Public Offerings

Elucidation:

As of December 31, 2025, the Company has fully realized the utilization of all proceeds from its respective public offerings as follows:

- Public Offering of Pyridam Farma Continuous Bonds I Phase III Year 2024: Fully utilized amounting to Rp321,594,822,184.- as set forth in the Use of Proceeds from the Public Offering of Pyridam Farma Continuous Bonds I Phase III Year 2024 Report, under Letter No. 009/PYFA-CS/I/2026 dated January 15, 2026.
- Public Offering of Pyridam Farma Continuous Bonds II Phase I Year 2025: Fully utilized amounting to Rp400,000,000,000.- as set forth in the Use of Proceeds from the Public Offering of Pyridam Farma Continuous Bonds II Phase I Year 2025 Report, under Letter No. 011/PYFA-CS/I/2026 dated January 15, 2026, and Letter No. 011a/PYFA-CS/II/2026 dated February 4, 2026.
- Limited Public Offering to Shareholders for Capital Increase with Pre-emptive Rights I and the proceeds from the conversion of Series I Warrants into shares amounting to Rp10,235,200.- as set forth in the Realization of the Use of Proceeds Report under No. 010/PYFA-CS/I/2026 dated January 15, 2026."

Sixth Agenda

Approval of amendments to the Company's Articles of Association, specifically the adjustment of the formulation regarding the Company's Business Activities as set forth in the provisions of Article 3 of the Company's Articles of Association concerning the Purposes and Objectives as well as Business Activities of the Company against the Regulation of the Central Bureau of Statistics Number 7 of 2025 concerning the Indonesia Standard Industrial Classification (KBLI 2025).

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter (f) of the Company's Articles of Association.
- (ii) Article 88 paragraph (1) of the Company Law, Article 42 letter a and letter b of the GMS POJK, and Article 26 paragraph (4) letter (a) and (b) of the Company's Articles of Association.
- (iii) Regulation of the Central Bureau of Statistics Number 7 of 2025 concerning the Indonesia Standard Industrial Classification.

Elucidation:

The approval for the amendment of Article 3 of the Articles of Association concerning the Company's Purposes, Objectives, and Business Activities is intended to ensure alignment with the 2025 Indonesia Standard Industrial Classification (KBLI) (pursuant to the Regulation of the Central Bureau of Statistics Number 7 of 2025 concerning the 2025 Indonesia Standard Industrial Classification). Consequently, such adjustment shall not be deemed a change of Business Activities (as contemplated under POJK No. 17/POJK.04/2020 concerning Material Transactions and Changes in Business Activities).

Seventh Agenda

Approval of Changes to the Composition of the Company's Management.

The underlying rationales of the proposed agenda are:

- (i) Article 13 paragraph (5) letter d of the Company's Articles of Association
- (ii) Article 111 paragraph (1) of the Company Law
- (iii) Article 3 paragraph (1) jo. Article 23 of POJK Number 33/POJK.04/2014 concerning Directors and Commissioners of Issuers or Public Companies

Elucidation:

- Changes in the Composition of the Composition of the Company's Management.

Lampiran - Profil Singkat (CV) Calon Pengurus Perseroan



Widjanarko Brotosaputro
61 years old, Indonesian.

He holds a degree in Medicine from Tarumanagara University (1991) and a Master of Management from Prasetiya Mulya Business School (2002). Throughout his career, he has held various strategic positions within the pharmaceutical industry, including:

Sales & Marketing Director at PT Yarindo Farmatama (Fahrenheit) (2006–2007); Business Development Head, Head of Marketing Ethical, Head of Sales and Marketing Pharma, VP Marketing Pharma, and Director at PT Combiphar (2007–2013); VP Marketing & Business Development at PT Meprofarm (2014–2015); Business Unit Director at PT Ikapharmindo Putramas (January 2016–December 2016); and Head of Sales, Marketing, and Business Development at PT Pyridam Farma Tbk (2017–2019), followed by a tenure as Director at PT Pyridam Farma Tbk (2019–2025). Currently, He serves as a Commissioner at PT Pyridam Farma Tbk and PT Medika Inovasi Nusantara, as well as the President Commissioner at PT Wahana Interfood Nusantara Tbk., PT Ethica Industri Farmasi, and PT Holi Pharma.

Informations:

This Meeting Agenda Material is prepared in accordance with the provisions of Article 18 paragraph (1) and (2) of the POJK on GMS, which inter alia requires a Public Company to make meeting agenda materials accessible and downloadable for shareholders via the Public Company's website and/or the e-GMS system. These materials must remain available from the GMS notice date until the staging of the GMS itself, save for the exceptions as provided under Article 18 paragraph (3). Should other laws and regulations mandate the availability of meeting agenda materials prior to the period mentioned in paragraph (2), the provisioning of such materials shall be governed by the respective laws and regulations